Description: Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company's Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.
Home Page: www.insmed.com
INSM Technical Analysis
700 US Highway 202/206
Bridgewater,
NJ
08807
United States
Phone:
908 977 9900
Officers
| Name | Title |
|---|---|
| Mr. William H. Lewis J.D., M.B.A. | Pres, CEO & Chairman |
| Ms. Sara M. Bonstein MBA | Chief Financial Officer |
| Mr. Roger Adsett | Chief Operating Officer |
| Ms. S. Nicole Schaeffer | Chief People Strategy Officer |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer |
| Mr. John Goll III | Sr. VP & Chief Accounting Officer |
| Eleanor Barisser | Associate Director of Investor Relations |
| Mr. Michael Alexander Smith | Sr. VP & Gen. Counsel |
| Mandy Fahey | Exec. Director of Corp. Communications |
| Mr. John Drayton Wise | Sr. VP, Head of United States & Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 48.1776 |
| Price-to-Sales TTM: | 10.886 |
| IPO Date: | 2000-06-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 613 |